In Vitro Release Profile and In-Vivo Pharmacokinetic Parameters of Ziprasidone Hydrochloride Bilayer Tablet for Schizophrenia Treatment

Abstract

Psychosis is a prominent symptom of schizophrenia and other psychotic illnesses, as well as a common but variable component of mood and substance use disorders and a somewhat common symptom of many developmental, acquired, and degenerative neurological and medical conditions. People with these disorders often struggle because psychosis makes it difficult for them to function in everyday life. As a result, neurologists and psychiatrists frequently assess and treat patients for psychosis as part of their care. In the present study, we developed a bilayer tablet of Ziprasidone and evaluated it for in vitrodrug release and pharmacokinetic analysis. The in vitro drug release study was conducted in Dissolution Apparatus Type II at pH 7.4, and the release kinetics were calculated for Zero order release rate, Korsmeyer-Pepas model, Hixson Crowell’s cube root curve, and First-order release curve. Moreover, the pharmacokinetic profile was conducted in Wistar rats weighing 260 to 280 gm. The in vitro drug release of the optimized batch shows 96.8 ± 6.78 % releases at 660 minutes. However, the pharmacokinetic parameters are found to be satisfactory. Thus, the outcomes of the study revealed that the prepared Ziprasidone bilayer tablet shows sustained release behaviour with better therapeutic outcomes.